切换至 "中华医学电子期刊资源库"

中华口腔医学研究杂志(电子版) ›› 2016, Vol. 10 ›› Issue (05) : 352 -355. doi: 10.3877/cma.j.issn.1674-1366.2016.05.010

所属专题: 口腔医学 文献

综述

靶向变异链球菌谷氨酸消旋酶的研究进展
张剑英1, 凌均棨2,()   
  1. 1. 410008 长沙,中南大学湘雅口腔医院牙体牙髓病科
    2. 510055 广州,中山大学光华口腔医学院·附属口腔医院,广东省口腔医学重点实验室
  • 收稿日期:2016-09-01 出版日期:2016-10-01
  • 通信作者: 凌均棨
  • 基金资助:
    国家自然科学基金(81371132); 广东省科技计划(2013B021800138)

Research progress on the targeting of glutamate racemase of Streptococcus mutans

Jianying Zhang1, Junqi Ling2,()   

  1. 1. Department of Operative Dentistry and Endodontics, Xiangya Stomatological Hospital, Central South University, Changsha 410008, China
    2. Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Stomatology, Guangzhou 510055, China
  • Received:2016-09-01 Published:2016-10-01
  • Corresponding author: Junqi Ling
  • About author:
    Corresponding author: Ling Junqi, Email:
引用本文:

张剑英, 凌均棨. 靶向变异链球菌谷氨酸消旋酶的研究进展[J]. 中华口腔医学研究杂志(电子版), 2016, 10(05): 352-355.

Jianying Zhang, Junqi Ling. Research progress on the targeting of glutamate racemase of Streptococcus mutans[J]. Chinese Journal of Stomatological Research(Electronic Edition), 2016, 10(05): 352-355.

变异链球菌是龋病发生的始动因子,与人类龋病密切相关。抑制变异链球菌致龋毒力相关的基因和酶,可影响细菌毒力因子的产生,降低细菌的致龋能力,有助于龋病的预防和治疗。谷氨酸消旋酶是一类不需辅助因子,专一催化L型和D型谷氨酸之间相互转化的酶,为细胞壁肽聚糖合成提供D-谷氨酸,是细菌生长的关键酶,目前已经成为研究和开发新型抗菌药物的新靶标。特异性靶向变异链球菌谷氨酸消旋酶,有望为龋病防治提供新的思路和方法。本文对谷氨酸消旋酶的分类、结构特征、酶抑制剂及基因遗传学等研究进展进行系统阐述,为进一步研究谷氨酸消旋酶与变异链球菌致龋毒力的关系,研发抗龋药物候选靶标提供理论基础。

Streptococcus mutans (S.mutans) is widely considered to be the major etiological factor responsible for dental caries in humans. Strategies selectively inhibiting the specific virulence factors associated with its cariogenicity are promising. Glutamate racemase (MurI) is a cofactor-independent enzyme that catalyzes the interconversion of L-glutamate to D-glutamate, one of the essential amino acids present in the peptidoglycan. As the indispensable enzyme in peptidoglycan biosynthesis, MurI has therefore been an attractive target for therapeutic interventions. In this review, the classifications, structures, inhibitors and genetic studies of MurI are systematically summarized. A comprehensive understanding of the relationship between MurI and cariogenic virulence of S.mutans can provide an important theoretical basis for potential therapeutic applications of dental caries.

[1]
Banas JA. Virulence properties of Streptococcus mutans[J]. Front Biosci,2004(9):1267-1277.
[2]
凌均棨.变形链球菌感受态形成的基因调控网络[J].中华口腔医学杂志,2015,50(6):342-345.
[3]
Bugg TD, Braddick D, Dowson CG,et al. Bacterial cell wall assembly:still an attractive antibacterial target[J]. Trends Biotechnol,2011,29(4):167-173.
[4]
Barreteau H, Kovac A, Boniface A,et al. Cytoplasmic steps of peptidoglycan biosynthesis[J]. FEMS Microbiol Rev,2008,32(2):168-207.
[5]
Cava F, Lam H, de Pedro MA,et al. Emerging knowledge of regulatory rols of D-amino acids in bacteria[J]. Cell Mol Life Sci,2011,68(5):817-813.
[6]
Ayengar P, Roberts E. Utilization of D-glutamic acid by Lactobacillus arabinosus:glutamic racemase[J]. J Biol Chem,1952,197(1):453-460.
[7]
Balikó G, Venetianer P. An Escherichia coli gene in search of a function:phenotypic effects of the gene recently identified as murI[J]. J Bacteriol,1993,175(20):6571-6577.
[8]
Lundqvist T, Fisher SL, Kern G,et al. Exploitation of structural and regulatory diversity in glutamate racemases[J]. Nature,2007,447(7146):817-822.
[9]
Kim KH, Bong YJ, Park JK,et al. Structural basis for glutamate racemase inhibition[J]. J Mol Biol,2007,372(2):434-443.
[10]
Kim WC, Rhee HI, Park BK,et al. Isolation of peptide ligands that inhibit glutamate racemase activity from a random phage display library[J]. J Biomol Screen,2000,5(6):435-440.
[11]
Kimura K, Tran LS, Itoh Y. Roles and regulation of the glutamate racemase isogenes,racE and yrpC,in Bacillus subtilis[J]. Microbiology,2004,150(Pt 9):2911-2920.
[12]
Sengupta S, Nagaraja V. Inhibition of DNA gyrase activity by Mycobacterium smegmatis MurI[J]. FEMS Microbiol Lett,2008,279(1):40-47.
[13]
Fisher SL. Glutamate racemase as a target for drug discovery[J]. Microbial Biotechnology,2008,1(5):345-360.
[14]
Pucci MJ, Thanassi JA, Ho HT,et al. Staphylococcus haemolyticus contains two D-glutamic acid biosynthetic activities,a glutamate racemase and a D-amino acid transaminase[J]. J Bacteriol,1995,177(2):336-342.
[15]
de Jonge BL, Kutschke A, Newman JV,et al. Pyridodiazepine amines are selective therapeutic agents for Helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy[J]. Antimicrob Agents Chemother,2015,59(4):2337-2342.
[16]
Gallo KA, Knowles J. Purification,cloning,and cofactor independence of glutamate racemase from Lactobacillus[J]. Biochemistry,1993,32(15):3981-3990.
[17]
Nakajima N, Tanizawa K, Tanaka H,et al. Cloning and expression in Escherichia coli of the glutamate racemase gene from Pediococcus pentosaceus[J]. Agric Biol Chem,1986,50(11):2823-2830.
[18]
Bhagavan NV. Medical biochemistry. Chapter 6:Enzymes I:General Properties,Kinetics,and Inhibition[M]. 4th ed. Academic Press,2001:85-108.
[19]
Ashiuchi M, Yoshimura T, Esaki N,et al. Inactivation of glutamate racemase of Pediococcus pentosaceus with L-serine-O-sulfate[J]. Biosci Biotech Biochem,1993,57(11):1978-1979.
[20]
Glavas S, Tanner ME. The inhibition of glutamate racemase by D-N-hydroxylglutamate[J]. Bioorg Med Chem Let,1997,7(17):2265-2270.
[21]
Tanner ME, Miao S. The synthesis and stability of aziridino-glutamate,an irreversible inhibitor of glutamate racemase[J]. Tet Let,1994,35(24):4073-4076.
[22]
de Jonge BL, Kutschke A, Uria-Nickelsen M,et al. Pyrazolopyrimidinediones are selective agents for Helicobacter pylori that suppress growth through inhibition of glutamate racemase(MurI)[J]. Antimicrob Agents Chemother,2009,53(8):3331-3336.
[23]
Choi SY, Esaki N, Ashiuchi M,et al. Bacterial glutamate racemase has high sequence similarity with myoglobins and forms an equimolar inactive complex with hemin[J]. Proc Natl Acad Sci USA,1994,91(21):10144-10147.
[24]
Corrigan RM, Abbott JC, Burhenne H,et al. c-di-AMP is a new second messenger in Staphylococcus aureus with a role in controlling cell size and envelope stress[J]. PLoS Pathog,2011,7(9):e1002217.
[25]
Doublet P, van Heijenoort J, Bohin JP,et al. The murI gene of Escherichia coli is an essential gene that encodes a glutamate racemase activity[J]. J Bacteriol,1993,175(10):2970-2979.
[26]
Morayya S, Awasthy D, Yadav R,et al. Revisiting the essentiality of glutamate racemase in Mycobacterium tuberculosis[J]. Gene,2015,555(2):269-276.
[27]
Li Y, Mortuza R, Milligan DL,et al. Investigation of the essentiality of glutamate racemase in Mycobacterium smegmatis[J]. J Bacteriol,2014,196(24):4239-4244.
[28]
Oh SY, Richter SG, Missiakas DM,et al. Glutamate racemase mutants of Bacillus anthracis[J]. J Bacteriol,2015,197(11):1854-1861.
[29]
Zhang J, Liu J, Ling J,et al. Inactivation of glutamate racemase(MurI)eliminates virulence in Streptococcus mutans[J]. Microbiol Res,2016(186-187):1-8.
[30]
樊明文.牙体牙髓病学[M]. 4版.北京:人民卫生出版社,2012:18.
[1] 王青青, 耿翠芝, 苏晓雨, 彭玉晓, 秦明祎, 刘风侠. 乳腺癌芳香化酶抑制剂相关肌肉骨骼不良反应的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(04): 243-249.
[2] 马敏榕, 李聪, 周勤. 宫颈癌治疗研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 497-504.
[3] 林昌盛, 战军, 肖雪. 上皮性卵巢癌患者诊疗中基因检测及分子靶向药物治疗[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 505-510.
[4] 张龙飞, 高涌, 张懿刚, 余朝文, 刘德朗, 刘亚, 陈世远. 载脂蛋白B、性激素结合球蛋白及金属蛋白酶组织抑制剂-1在皖北地区原发性下腔静脉隔膜型布加综合征的临床意义[J]. 中华普通外科学文献(电子版), 2023, 17(04): 252-256.
[5] 中国康复医学会器官移植康复专业委员会. 成人实体器官移植后糖尿病管理专家共识[J]. 中华移植杂志(电子版), 2023, 17(04): 205-220.
[6] 巨春蓉, 何建行, 钟南山. 咪唑立宾在器官移植领域的应用及展望[J]. 中华移植杂志(电子版), 2023, 17(04): 227-231.
[7] 徐烨, 李婧, 刘冉佳, 潘晨, 郭明星, 崔向丽. 2017至2021年中国95家医疗机构肝移植术后免疫抑制剂用药分析[J]. 中华移植杂志(电子版), 2023, 17(03): 134-139.
[8] 刘路浩, 苏泳鑫, 曾丽娟, 张鹏, 陈荣鑫, 徐璐, 李光辉, 方佳丽, 马俊杰, 陈正. 新型冠状病毒感染疫情期间肾移植受者免疫抑制剂服药依从性研究[J]. 中华移植杂志(电子版), 2023, 17(03): 140-145.
[9] 刘恒, 侯宇川. 膀胱癌新型灌注药物的研究进展[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 445-451.
[10] 王秀清, 诸葛金科, 杨明星, 董文. ICIs治疗肺癌并发肺气肿致免疫相关性肺炎的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 400-402.
[11] 张沥, 宋俊华, 何皓, 杨雪瑶, 周康. 血清D-D、PAI-1、sICAM-1水平与糖尿病合并肺部感染病情严重程度及预后的关系[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 203-205.
[12] 杨秀君, 崔梦莹, 张丹, 曲仙智, 苗云皓, 盛基尧, 郑戈, 刘水, 张学文. 信迪利单抗联合仑伐替尼成功转化治疗不可切除肝癌一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 581-584.
[13] 蔡晨, 龚伟. 免疫治疗在胆道肿瘤中的应用现状及展望[J]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 162-166.
[14] 程庆砾. 免疫抑制剂在肾小球疾病中的合理使用[J]. 中华肾病研究电子杂志, 2023, 12(02): 120-120.
[15] 梁文龙, 曹杰, 黄庆, 林泳, 黄红丽, 杨平, 李冠炜, 胡鹤. 信迪利单抗联合瑞戈非尼治疗晚期结直肠癌的疗效与安全性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 409-413.
阅读次数
全文


摘要